AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage (LAA) Exclusion System products are the most widely used LAA management devices in the world. AtriCure’s Cryo Nerve Block Therapy helps manage post-operative pain by temporarily blocking pain signals from peripheral nerves around the surgical site. Axons that send pain signals degenerate following freezing and start regenerating afterwards, allowing for nerve function to resume over the course of several months.